SWM
BIOL

Spire Wealth Management’s Biolase, Inc. BIOL Stock Holding History

Spire Wealth Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2
Closed -$3K – 2669
2021
Q2 		$3K Buy
+2
New +$3.71K ﹤0.01% 2447

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spire Wealth Management's BIOL Position: Q3 2021 in Review

Spire Wealth Management sold out of Biolase, Inc. (BIOL) in Q3 2021, closing a stake of 2 shares — an estimated $3K sold.

Spire Wealth Management first reported a position in BIOL in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 38 funds tracked by Wall St. Rank hold BIOL as of Q3 2021.

  • Spire Wealth Management reported no remaining Biolase, Inc. position as of Q3 2021 after selling out during the quarter.
  • Spire Wealth Management sold 2 Biolase, Inc. shares in Q3 2021, an estimated $3K.
  • Spire Wealth Management first reported a position in Biolase, Inc. in Q2 2021 and held it in 1 quarter.
  • Spire Wealth Management's Biolase, Inc. position peaked at $3K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2021.

Based on Spire Wealth Management's 13F filing for Q3 2021, filed 22 Oct 2021.